Aclarion Inc. (Nasdaq: ACON, ACONW), the Broomfield healthcare technology company focused on chronic low back pain, announced an update on its improved positioning following successful strategic initiatives in the first quarter of 2025.
The company raised over $20 million in Q1, maintaining nearly $15 million in cash on hand. Aclarion reported a clean capital structure, with no debt, no preferred equity and no warrants with strike prices near the current market. The company is fully compliant with Nasdaq requirements, meeting both bid price and shareholder equity standards.
Aclarion’s pivotal CLARITY trial is fully funded, with initial interim results expected by Q2 2026. “Aclarion significantly improved its financial and Nasdaq compliance positioning throughout Q1 such that we are now very well positioned to execute on our strategic plan of driving Nociscan to standard of care,” said Dr. Jeff Thramann, executive chairman of Aclarion.
Brent Ness, CEO of Aclarion, noted, “The company is accelerating across all areas of execution. In addition to strong momentum enrolling CLARITY sites, we’ve made meaningful commercial progress.” He highlighted recent payer approvals in England and expanding support among physicians and radiologists in the U.S. for the Nociscan solution, which objectively quantifies chemical biomarkers related to disc pain.
